Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -2.7% Market Closed
Market Cap: 190.4m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

P/E
Price to Earnings

-21.6
Current
-4.1
Median
21.9
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-21.6
=
Market Cap
189.1m AUD
/
Net Income
-8.7m AUD
All Countries
Close
Earnings Growth
AU
Arovella Therapeutics Ltd
ASX:ALA
Average P/E: 33.2
Negative Multiple: -21.6
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
88.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
34.9
86%
US
Johnson & Johnson
NYSE:JNJ
25.5
-22%
US
Merck & Co Inc
NYSE:MRK
21.3
7 321%
CH
Roche Holding AG
SIX:ROG
17.4
32%
UK
AstraZeneca PLC
LSE:AZN
31.8
177%
CH
Novartis AG
SIX:NOVN
11.6
21%
US
Pfizer Inc
NYSE:PFE
34.5
733%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-17.7
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A

See Also

Discover More